Medical technology company Amber Therapeutics has signed for 7,000 sq ft of space at the Tech Foundry development at Harwell Campus for its new HQ.
The company, which was was founded in 2021 with backing from Oxford Science Enterprises (OSE), will use the facility for R&D, manufacturing and production purposes.
David Williams, commercial director at Harwell Campus, said: “We’re delighted to welcome Amber Therapeutics to Harwell. We designed Tech Foundry to provide flexible, sustainable space for fast growing, highly technical companies. It’s the ideal space for Amber to scale their operations and advance their world leading technology in our thriving health tech cluster.”
Aidan Crawley, co-founder and CEO of Amber Therapeutics, added: “The Amber team is delighted to be relocating to Harwell. Our new HQ will become the only manufacturer and producer of Class III active implantable devices in the UK and we believe this site will be an absolute state of the art R&D facility that can fuel the development not just of our initial Amber UI therapy, but the pipeline of ideas that our platform capability has in store.”
